Skip to content
VuFind
  • Login
    • English
    • اللغة العربية
Advanced
  • TFAB002s exhibited binding aff...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
TFAB002s exhibited binding affinity towards FcRn.

TFAB002s exhibited binding affinity towards FcRn.

<p>FACS was performed to assess TFAB002s’ binding ability with FcRn on H_FCGR2B CHO-K1 cells (A) at pH 6.0 and (B) at pH 7.4.</p>

Saved in:
Bibliographic Details
Main Author: Qinghong Li (5003339) (author)
Other Authors: Kunming Zhang (5919659) (author), Yao Yu (137213) (author), Zeng Yu (2286916) (author), Jingyi Xu (6522) (author), Wenyan Shen (5333102) (author), Lin Zhang (8926) (author), Aidong Qu (11566824) (author), Hongyuan Liang (9909840) (author)
Published: 2024
Subjects:
Biophysics
Biochemistry
Cell Biology
Pharmacology
Biotechnology
Immunology
Cancer
Hematology
Biological Sciences not elsewhere classified
Chemical Sciences not elsewhere classified
moderate binding affinity
express varying levels
encompass various subtypes
binding fragment 002
dependent bispecific fab
dependent bispecific antibodies
selectively depleting cd20
thereby triggering target
viable treatment option
tumor cell lysis
positive b cells
div >< p
specifically target cd20
optimal target
thereby warranting
constructing fab
therapeutic antibodies
novel cd20
vivo </
vitro </
tfab002 ),
tandem antigen
results underscore
novel non
normal tissues
malignant b
heterogeneous group
expressing b
cytokine release
clinical evaluation
cell lymphoma
cell activation
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Holdings
  • Description
  • Comments
  • Similar Items
  • Staff View
Be the first to leave a comment!
You must be logged in first

Similar Items

  • TFAB002s exhibited significant binding affinity towards CD20 and CD3.
    by: Qinghong Li (5003339)
    Published: (2024)
  • TFAB002s did not exhibit binding affinity towards CHO-K1 cells.
    by: Qinghong Li (5003339)
    Published: (2024)
  • TFAB002s exhibited favorable safety and efficacy <i>in vivo</i>.
    by: Qinghong Li (5003339)
    Published: (2024)
  • TFAB002s’ biological activity was observed to be similar across different tumor cell lines.
    by: Qinghong Li (5003339)
    Published: (2024)
  • TFAB002s activated T cells and promoted T-cell mediated killing of lymphoma B cells.
    by: Qinghong Li (5003339)
    Published: (2024)

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items
Cannot write session to /tmp/vufind_sessions/sess_ta3dob37of5go0ip97qu26osag